Navigation Links
Shire Regenerative Medicine Initiates Phase 3 Study of ABH001 for Patients with Epidermolysis Bullosa
Date:2/8/2013

d three years and older are planned to enroll in the trial, which is targeted to be conducted in 10 to 15 sites across the US, Europe and Canada. The study will comprise ABH001 applications sufficient to cover the surface area of the wound, applied topically every 4 weeks with protocol-specified dressings until healed or for up to 24 weeks.

"We are excited that Shire Regenerative Medicine has launched this trial," said Brett Kopelan , Executive Director of the Dystrophic EB Research Association of America (DebRA ) and father to a 5-year-old girl with recessive dystrophic EB.  "While there is currently no cure for EB, I am encouraged that ABH001 is…targeting the chronic wounds that are the hallmark of this disease. I applaud Shire for pushing this forward and look forward to working closely with them as the trial progresses."  

"We are very eager to begin evaluating ABH001 as a potential wound treatment option for people with EB. We believe it has the potential to initiate and continue wound healing in this patient population," said Jeff Jonas , MD, President of Shire Regenerative Medicine. "We are committed to developing regenerative medicine solutions that enable people with life-altering conditions to lead better lives, and are encouraged by the fast track and orphan drug designations we have received to further develop this potential therapy for people, most often young children, suffering from this devastating condition."

Shire is also developing an intravenous protein replacement therapy for the treatment of dystrophic EB, which the company's Human Genetic Therapies business recently acquired from Lotus Tissue Repair, Inc. Initiation of this pivotal trial of ABH001 for patients with EB further demonstrates Shire's commitment to developing a portfolio of products targeted toward patients who suffer from this di
'/>"/>

SOURCE Shire plc
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Shire to Acquire FerroKin BioSciences, Inc., and its Phase 2 Iron Chelator Treatment
2. Heptares Grants Shire an Exclusive Worldwide Licence to Develop and Commercialise Novel Drug Candidate for CNS Disorders
3. Shire plc: First Quarter 2012 Results Date Notification - April 26, 2012
4. Shire Facebook Page Increases Awareness of Hereditary Angioedema (HAE) in Support of First HAE Awareness Day May 16th
5. Berkshire Corporation Offers Live Chat For Americas Website and Shopping Cart
6. Shire Changes its NASDAQ Ticker Symbol to SHPG
7. Dr. Jeff Jonas Appointed President of Shire Regenerative Medicine Business and Joins Shire Leadership Team
8. Shire and Boston Childrens Hospital Enter Into Broad Research Collaboration
9. Shire Reaches Agreement in Principle With U.S. Government
10. Palm Beach Residents to Learn How the Future of Regenerative Medicine Will Combat Aging
11. ODT Forum Presents Regenerative Technologies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Antonio, TX (PRWEB) August 29, 2014 ... and ISO 13485:2003 certified, GAMP® 5 compliant imaging ... awarded an international Phase II clinical trial to ... lymphoma. , Throughout this trial, Intrinsic Imaging will ... not limited to, protocol and charter development, site ...
(Date:8/28/2014)... Best Sanitizers, Inc., the first company ... sanitizer, asks food processors and food handling professionals to ... they’re currently using to Best Sanitizers’ Alpet® E3 ... to fighting cross-contamination and the spread of pathogens in ... are key criteria that make a hand sanitizer most ...
(Date:8/28/2014)... important devices in spintronics, an electronic which is ... but also on their spin and the spin-related ... into magnetic signals and vice versa. Recently, the ... Institute of Physics at Johannes Gutenberg University Mainz ... and Japan, has for the first time realised ...
(Date:8/28/2014)...  Next month, executives from clinical trial marketing firm BBK ... with Patient-Centered Clinical Trials 2014 , to be held ... , September 4-5. Patient recruitment experts Bonnie A. Brescia ... will share insights on the benefits of employing an effective ... from media to mobile apps – can be used to ...
Breaking Biology Technology:Intrinsic Imaging Awarded Phase II Clinical Trial to Assess New Treatment for Non-Hodgkin’s Lymphoma 2Food Processors and Food Handlers are Encouraged to Prepare for Fall Harvest by Evaluating Their Current Hand Sanitizer Using Nine Key Criteria 2Food Processors and Food Handlers are Encouraged to Prepare for Fall Harvest by Evaluating Their Current Hand Sanitizer Using Nine Key Criteria 3A new, tunable device for spintronics 2A new, tunable device for spintronics 3BBK Worldwide Leads Sessions at Key September Events 2
... 9, 2012 First tenant moves in ... bioscience campus, is pleased to announce that it is now ... tenant, Aptiv Solutions , which has taken space in ... to be a busy one - discussions with a range ...
... Calif., Feb. 7, 2012  New England Biolabs, Inc. (NEB) and ... entered into a licensing agreement whereby NEB will introduce ... technology developed by Dr. Daniel Gibson and his colleagues ... of a program sponsored by SGI. The financial details ...
... DIEGO, Feb. 6, 2012 Neurocrine Biosciences, Inc. (Nasdaq: ... Chief Executive Officer of Neurocrine Biosciences, will be presenting at ... York.    The live presentation takes place on ... a.m. Pacific Time.  The presentation will be webcast and may ...
Cached Biology Technology:Stevenage Bioscience Catalyst Opens With Exciting Year Ahead 2Stevenage Bioscience Catalyst Opens With Exciting Year Ahead 3Stevenage Bioscience Catalyst Opens With Exciting Year Ahead 4Stevenage Bioscience Catalyst Opens With Exciting Year Ahead 5Stevenage Bioscience Catalyst Opens With Exciting Year Ahead 6New England Biolabs Signs Agreement with Synthetic Genomics Inc. to Launch Gibson Assembly™ Master Mix for Molecular and Synthetic Biology Applications 2New England Biolabs Signs Agreement with Synthetic Genomics Inc. to Launch Gibson Assembly™ Master Mix for Molecular and Synthetic Biology Applications 3
(Date:8/29/2014)... made some surprising discoveries about the body,s initial ... (SIV), the team found that specialized cells in ... to viral invasion and are the source of ... beta (IL-1β). , Though aimed at the ... gut epithelium that provides a barrier to protect ...
(Date:8/29/2014)... from the University of Texas Medical Branch at Galveston has ... antibodies can completely protect monkeys against a lethal dose of ... time when the disease is severe. , Thomas Geisbert, professor ... Nature discussing advances in Ebola treatment research. The filoviruses ... most deadly of pathogens, with fatality rates of up to ...
(Date:8/29/2014)... news release is available in German . ... key players in the natural nitrogen cycle on Earth ... specialist bacteria were thought to depend on nitrite as ... led by Holger Daims, a microbiologist at the University ... use hydrogen as an alternative source of energy. The ...
Breaking Biology News(10 mins):The early cost of HIV 2Leading Ebola researcher at UTMB says there's an effective treatment for Ebola 2Hydrogen powers important nitrogen-transforming bacteria 2Hydrogen powers important nitrogen-transforming bacteria 3
... a new compound that restores the health of mice ... otherwise dangerous bacterial infection. The new compound targets an ... essential to bacterial survival. The research team, led ... University of California, San Diego, reports the new findings ...
... The Damon Runyon Cancer Research Foundation announced that ... been named 2013 recipients of the Damon Runyon-Rachleff Innovation ... is awarded each year to early career scientists whose ... diagnosis and treatment of cancer. ...
... of North Carolina School of Medicine are shining a light ... matter, or "junk DNA," within each of our genes. ... matter that can alter the way a gene is assembled. ... how to splice, either by enhancing the splicing process or ...
Cached Biology News:New compound overcomes drug-resistant Staph infection in mice 2New compound overcomes drug-resistant Staph infection in mice 3Damon Runyon-Rachleff Innovation Awards granted for pioneering ideas in cancer research 2Damon Runyon-Rachleff Innovation Awards granted for pioneering ideas in cancer research 3Damon Runyon-Rachleff Innovation Awards granted for pioneering ideas in cancer research 4Damon Runyon-Rachleff Innovation Awards granted for pioneering ideas in cancer research 5Dark matter made visible before the final cut 2Dark matter made visible before the final cut 3
...
A component of the Acridinium protein labeling kit....
... detection system holds 48 x 0.2 ml tubes, ... LEDs independently excites fluorescence (470-500 nm) for each ... emitted light (523-543 nm and 540-700 nm). The ... whose Peltier heat pumps provide superb thermal performance. ...
... Automated instrument designed to hold up to 6 ... robust and easy to use design ensures that ... regular cyclic stretching or compression. This unit allows ... the strain to produce 64 unique strain settings. ...
Biology Products: